Investigation of interaction between sodium-glucose cotransporter 2 inhibitors and FOLFOX with colorectal cancer and type 2 diabetes

Table 2 Comparison of glycemic control between the two groups, mean ± SD

Indicators	Time	Control group (n = 80)	Experimental group (n = 80)	t/χ2	P value
Glycated hemoglobin (%)	Before treatment	8.06 ± 0.84	8.02 ± 0.83	0.310	0.757
	After treatment	7.75 ± 0.59	6.79 ± 0.79	8.671	< 0.001
Fasting blood glucose (mmol/L)	Before treatment	7.81 ± 1.93	7.85 ± 1.89	-0.130	0.896
	After treatment	7.45 ± 1.29	6.75 ± 1.56	3.106	0.002

It compares glycated hemoglobin and fasting blood glucose levels before and after treatment between the control and experimental groups using paired sample t-tests. The results show that while no significant differences existed at baseline (P > 0.05), the experimental group achieved significantly greater reductions in both glycated hemoglobin and fasting blood glucose levels after treatment compared to the control group (P < 0.05).